{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:10:37Z","timestamp":1760609437303,"version":"3.37.3"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P33062"],"award-info":[{"award-number":["P33062"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Land Tirol Forschungsf\u00f6rderung, Project GZ 71934"},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["IIS 1199-0424"],"award-info":[{"award-number":["IIS 1199-0424"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The CovILD study is a prospective, multicenter, observational cohort study to systematically follow up patients after coronavirus disease-2019 (COVID-19). We extensively evaluated 145 COVID-19 patients at 3 follow-up visits scheduled for 60, 100, and 180\u00a0days after initial confirmed diagnosis based on typical symptoms and a positive reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We employed comprehensive pulmonary function and laboratory tests, including serum concentrations of IgG against the viral spike (S) glycoprotein, and compared the results to clinical data and chest computed tomography (CT). We found that at the 60\u00a0day follow-up, 131 of 145 (90.3%) participants displayed S-specific serum IgG levels above the cut-off threshold. Notably, the highly elevated IgG levels against S glycoprotein positively correlated with biomarkers of immune activation and negatively correlated with pulmonary function and the extent of pulmonary CT abnormalities. Based on the association between serum S glycoprotein-specific IgG and clinical outcome, we generated an S-specific IgG-based recovery score that, when applied in the early convalescent phase, accurately predicted delayed pulmonary recovery after COVID-19. Therefore, we propose that S-specific IgG levels serve as a useful immunological surrogate marker for identifying at-risk individuals with persistent pulmonary injury who may require intensive follow-up care after COVID-19.<\/jats:p>","DOI":"10.1038\/s41598-022-07489-6","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T11:06:11Z","timestamp":1646651171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Quantity of IgG response to SARS-CoV-2 spike glycoprotein predicts pulmonary recovery from COVID-19"],"prefix":"10.1038","volume":"12","author":[{"given":"Manfred","family":"Nairz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Sahanic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Pizzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Tymoszuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maria","family":"Mitterstiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"von Raffay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Grubwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Bellmann-Weiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Koppelst\u00e4tter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Schroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Haschka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Blunder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Trattnig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Naschberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1104-5613","authenticated-orcid":false,"given":"Werner","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Theurl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Gehrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Mindur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Luger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schwabl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlig","family":"Widmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0709-2158","authenticated-orcid":false,"given":"G\u00fcnter","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"L\u00f6ffler-Ragg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Tancevski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Sonnweber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"7489_CR1","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 324, 782\u2013793. https:\/\/doi.org\/10.1001\/jama.2020.12839 (2020).","journal-title":"JAMA"},{"key":"7489_CR2","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1038\/s41467-020-19509-y","volume":"11","author":"H Streeck","year":"2020","unstructured":"Streeck, H. et al. Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nat. Commun. 11, 5829. https:\/\/doi.org\/10.1038\/s41467-020-19509-y (2020).","journal-title":"Nat. Commun."},{"key":"7489_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003346","volume":"17","author":"D Buitrago-Garcia","year":"2020","unstructured":"Buitrago-Garcia, D. et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 17, e1003346. https:\/\/doi.org\/10.1371\/journal.pmed.1003346 (2020).","journal-title":"PLoS Med."},{"key":"7489_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay, M. Z., Poh, C. M., Renia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363\u2013374. https:\/\/doi.org\/10.1038\/s41577-020-0311-8 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"7489_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41569-020-0413-9","volume":"17","author":"M Nishiga","year":"2020","unstructured":"Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B. & Wu, J. C. COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives. Nat. Rev. Cardiol. 17, 543\u2013558. https:\/\/doi.org\/10.1038\/s41569-020-0413-9 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"7489_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nri3295","volume":"12","author":"NK Duggal","year":"2012","unstructured":"Duggal, N. K. & Emerman, M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat. Rev. Immunol. 12, 687\u2013695. https:\/\/doi.org\/10.1038\/nri3295 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"7489_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355\u2013362. https:\/\/doi.org\/10.1038\/s41577-020-0331-4 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"7489_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","volume":"20","author":"X Cao","year":"2020","unstructured":"Cao, X. COVID-19: Immunopathology and its implications for therapy. Nat. Rev. Immunol. 20, 269\u2013270. https:\/\/doi.org\/10.1038\/s41577-020-0308-3 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"7489_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.immuni.2020.07.005","volume":"53","author":"A Sariol","year":"2020","unstructured":"Sariol, A. & Perlman, S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity 53, 248\u2013263. https:\/\/doi.org\/10.1016\/j.immuni.2020.07.005 (2020).","journal-title":"Immunity"},{"key":"7489_CR10","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","volume":"71","author":"J Zhao","year":"2020","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin. Infect. Dis. 71, 2027\u20132034. https:\/\/doi.org\/10.1093\/cid\/ciaa344 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"7489_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","volume":"587","author":"J Braun","year":"2020","unstructured":"Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 587, 270\u2013274. https:\/\/doi.org\/10.1038\/s41586-020-2598-9 (2020).","journal-title":"Nature"},{"key":"7489_CR12","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.cell.2020.10.001","volume":"183","author":"BJ Meckiff","year":"2020","unstructured":"Meckiff, B. J. et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4(+) T cells in COVID-19. Cell 183, 1340\u20131353. https:\/\/doi.org\/10.1016\/j.cell.2020.10.001 (2020).","journal-title":"Cell"},{"key":"7489_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10040202","author":"SK Vashist","year":"2020","unstructured":"Vashist, S. K. In vitro diagnostic assays for COVID-19: Recent advances and emerging trends. Diagnostics https:\/\/doi.org\/10.3390\/diagnostics10040202 (2020).","journal-title":"Diagnostics"},{"key":"7489_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ajcp\/aqaa112","volume":"154","author":"AP Espejo","year":"2020","unstructured":"Espejo, A. P. et al. Review of current advances in serologic testing for COVID-19. Am. J. Clin. Pathol. 154, 293\u2013304. https:\/\/doi.org\/10.1093\/ajcp\/aqaa112 (2020).","journal-title":"Am. J. Clin. Pathol."},{"key":"7489_CR15","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2021-0214","author":"C Irsara","year":"2021","unstructured":"Irsara, C. et al. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Clin. Chem. Lab. Med. https:\/\/doi.org\/10.1515\/cclm-2021-0214 (2021).","journal-title":"Clin. Chem. Lab. Med."},{"key":"7489_CR16","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-1758","author":"C Irsara","year":"2020","unstructured":"Irsara, C. et al. Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay. Clin. Chem. Lab. Med. https:\/\/doi.org\/10.1515\/cclm-2020-1758 (2020).","journal-title":"Clin. Chem. Lab. Med."},{"key":"7489_CR17","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1038\/s41598-021-83108-0","volume":"11","author":"M Batra","year":"2021","unstructured":"Batra, M. et al. Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Sci. Rep. 11, 3455. https:\/\/doi.org\/10.1038\/s41598-021-83108-0 (2021).","journal-title":"Sci. Rep."},{"key":"7489_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41423-020-0474-z","volume":"17","author":"H Ma","year":"2020","unstructured":"Ma, H. et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell. Mol. Immunol. 17, 773\u2013775. https:\/\/doi.org\/10.1038\/s41423-020-0474-z (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"7489_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa784","author":"J Klingler","year":"2020","unstructured":"Klingler, J. et al. Role of IgM and IgA antibodies in the neutralization of SARS-CoV-2. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiaa784 (2020).","journal-title":"J. Infect. Dis."},{"key":"7489_CR20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01526-2020","author":"HQ Yu","year":"2020","unstructured":"Yu, H. Q. et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.01526-2020 (2020).","journal-title":"Eur. Respir. J."},{"key":"7489_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe0367","author":"AS Iyer","year":"2020","unstructured":"Iyer, A. S. et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abe0367 (2020).","journal-title":"Sci. Immunol."},{"key":"7489_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd2223","author":"D Sterlin","year":"2020","unstructured":"Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abd2223 (2020).","journal-title":"Sci. Transl. Med."},{"key":"7489_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf1555","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abf1555 (2020).","journal-title":"Sci. Transl. Med."},{"key":"7489_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jinf.2020.09.015","volume":"82","author":"D Orth-Holler","year":"2020","unstructured":"Orth-Holler, D., Eigentler, A., Stiasny, K., Weseslindtner, L. & Most, J. Kinetics of SARS-CoV-2 specific antibodies (IgM, IgA, IgG) in non-hospitalized patients four months following infection. J. Infect. 82, 282\u2013327. https:\/\/doi.org\/10.1016\/j.jinf.2020.09.015 (2020).","journal-title":"J. Infect."},{"key":"7489_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe5511","author":"B Isho","year":"2020","unstructured":"Isho, B. et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abe5511 (2020).","journal-title":"Sci. Immunol."},{"key":"7489_CR26","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.immuni.2020.10.004","volume":"53","author":"TJ Ripperger","year":"2020","unstructured":"Ripperger, T. J. et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity 53, 925\u2013933. https:\/\/doi.org\/10.1016\/j.immuni.2020.10.004 (2020).","journal-title":"Immunity"},{"key":"7489_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab300","author":"D Pichler","year":"2021","unstructured":"Pichler, D. et al. Marked increase in avidity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies 7\u20138 months after infection is not diminished in old age. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiab300 (2021).","journal-title":"J. Infect. Dis."},{"key":"7489_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab255","author":"L Yao","year":"2020","unstructured":"Yao, L. et al. Persistence of antibody and cellular immune responses in COVID-19 patients over nine months after infection. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiab255 (2020).","journal-title":"J. Infect. Dis."},{"key":"7489_CR29","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/eji.202048970","volume":"50","author":"P Figueiredo-Campos","year":"2020","unstructured":"Figueiredo-Campos, P. et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur. J. Immunol. 50, 2025\u20132040. https:\/\/doi.org\/10.1002\/eji.202048970 (2020).","journal-title":"Eur. J. Immunol."},{"key":"7489_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03207-w","author":"C Gaebler","year":"2020","unstructured":"Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature https:\/\/doi.org\/10.1038\/s41586-021-03207-w (2020).","journal-title":"Nature"},{"key":"7489_CR31","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.cell.2020.10.052","volume":"183","author":"T Zohar","year":"2020","unstructured":"Zohar, T. et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell 183, 1508\u20131519. https:\/\/doi.org\/10.1016\/j.cell.2020.10.052 (2020).","journal-title":"Cell"},{"key":"7489_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab295","author":"V De Giorgi","year":"2020","unstructured":"De Giorgi, V. et al. Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiab295 (2020).","journal-title":"J. Infect. Dis."},{"key":"7489_CR33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/cid\/ciaa979","volume":"72","author":"KL Lynch","year":"2020","unstructured":"Lynch, K. L. et al. Magnitude and kinetics of anti-severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity. Clin. Infect. Dis. 72, 301\u2013308. https:\/\/doi.org\/10.1093\/cid\/ciaa979 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"7489_CR34","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.04.410589","author":"NS Haddad","year":"2020","unstructured":"Haddad, N. S. et al. Elevated SARS-CoV-2 antibodies distinguish severe disease in early COVID-19 infection. BioRxiv https:\/\/doi.org\/10.1101\/2020.12.04.410589 (2020).","journal-title":"BioRxiv"},{"key":"7489_CR35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/ajcp\/aqaa123","volume":"154","author":"WS Phipps","year":"2020","unstructured":"Phipps, W. S. et al. SARS-CoV-2 antibody responses do not predict covid-19 disease severity. Am. J. Clin. Pathol. 154, 459\u2013465. https:\/\/doi.org\/10.1093\/ajcp\/aqaa123 (2020).","journal-title":"Am. J. Clin. Pathol."},{"key":"7489_CR36","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.abe1107","volume":"370","author":"KW Ng","year":"2020","unstructured":"Ng, K. W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370, 1339\u20131343. https:\/\/doi.org\/10.1126\/science.abe1107 (2020).","journal-title":"Science"},{"key":"7489_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41590-020-00826-9","volume":"22","author":"SP Weisberg","year":"2020","unstructured":"Weisberg, S. P. et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat. Immunol. 22, 25\u201331. https:\/\/doi.org\/10.1038\/s41590-020-00826-9 (2020).","journal-title":"Nat. Immunol."},{"key":"7489_CR38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.2020006520","volume":"136","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari, H. et al. COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 136, 489\u2013500. https:\/\/doi.org\/10.1182\/blood.2020006520 (2020).","journal-title":"Blood"},{"key":"7489_CR39","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(20)30920-X","volume":"395","author":"H Li","year":"2020","unstructured":"Li, H. et al. SARS-CoV-2 and viral sepsis: Observations and hypotheses. Lancet 395, 1517\u20131520. https:\/\/doi.org\/10.1016\/S0140-6736(20)30920-X (2020).","journal-title":"Lancet"},{"key":"7489_CR40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2007575","volume":"382","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19. N. Engl. J. Med. 382, e38. https:\/\/doi.org\/10.1056\/NEJMc2007575 (2020).","journal-title":"N. Engl. J. Med."},{"key":"7489_CR41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144455","author":"MS Abers","year":"2020","unstructured":"Abers, M. S. et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.144455 (2020).","journal-title":"JCI Insight"},{"key":"7489_CR42","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/07853890.2020.1840621","volume":"53","author":"N Broman","year":"2020","unstructured":"Broman, N. et al. IL-6 and other biomarkers as predictors of severity in COVID-19. Ann. Med. 53, 410\u2013412. https:\/\/doi.org\/10.1080\/07853890.2020.1840621 (2020).","journal-title":"Ann. Med."},{"key":"7489_CR43","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012421","volume":"12","author":"T Liu","year":"2020","unstructured":"Liu, T. et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol. Med. 12, e12421. https:\/\/doi.org\/10.15252\/emmm.202012421 (2020).","journal-title":"EMBO Mol. Med."},{"key":"7489_CR44","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12931-020-01546-2","volume":"21","author":"T Sonnweber","year":"2020","unstructured":"Sonnweber, T. et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients\u2019 performance: a prospective observational cohort study. Respir. Res. 21, 276. https:\/\/doi.org\/10.1186\/s12931-020-01546-2 (2020).","journal-title":"Respir. Res."},{"key":"7489_CR45","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03481-2020","author":"T Sonnweber","year":"2020","unstructured":"Sonnweber, T. et al. Cardiopulmonary recovery after COVID-19 - an observational prospective multi-center trial. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.03481-2020 (2020).","journal-title":"Eur. Respir. J."},{"key":"7489_CR46","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. Engl. J. Med. 383, 2255\u20132273. https:\/\/doi.org\/10.1056\/NEJMra2026131 (2020).","journal-title":"N. Engl. J. Med."},{"key":"7489_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","volume":"53","author":"N Mangalmurti","year":"2020","unstructured":"Mangalmurti, N. & Hunter, C. A. Cytokine storms: Understanding COVID-19. Immunity 53, 19\u201325. https:\/\/doi.org\/10.1016\/j.immuni.2020.06.017 (2020).","journal-title":"Immunity"},{"key":"7489_CR48","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nature05181","volume":"443","author":"JC Kash","year":"2006","unstructured":"Kash, J. C. et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 443, 578\u2013581. https:\/\/doi.org\/10.1038\/nature05181 (2006).","journal-title":"Nature"},{"key":"7489_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nature05495","volume":"445","author":"D Kobasa","year":"2007","unstructured":"Kobasa, D. et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445, 319\u2013323. https:\/\/doi.org\/10.1038\/nature05495 (2007).","journal-title":"Nature"},{"key":"7489_CR50","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore, J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. Science 368, 473\u2013474. https:\/\/doi.org\/10.1126\/science.abb8925 (2020).","journal-title":"Science"},{"key":"7489_CR51","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","volume":"8","author":"DE Leisman","year":"2020","unstructured":"Leisman, D. E. et al. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 8, 1233\u20131244. https:\/\/doi.org\/10.1016\/S2213-2600(20)30404-5 (2020).","journal-title":"Lancet Respir. Med."},{"key":"7489_CR52","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140329","author":"KE Remy","year":"2020","unstructured":"Remy, K. E. et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.140329 (2020).","journal-title":"JCI Insight"},{"key":"7489_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.16896","volume":"190","author":"PR Tepasse","year":"2020","unstructured":"Tepasse, P. R. et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: Two cases with fatal outcome and a review of the literature. Br. J. Haematol. 190, 185\u2013188. https:\/\/doi.org\/10.1111\/bjh.16896 (2020).","journal-title":"Br. J. Haematol."},{"key":"7489_CR54","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00296-020-04699-x","volume":"40","author":"J Loarce-Martos","year":"2020","unstructured":"Loarce-Martos, J. et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: A descriptive study. Rheumatol. Int. 40, 2015\u20132021. https:\/\/doi.org\/10.1007\/s00296-020-04699-x (2020).","journal-title":"Rheumatol. Int."},{"key":"7489_CR55","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/ajh.26209","volume":"96","author":"R Dul\u00e9ry","year":"2021","unstructured":"Dul\u00e9ry, R. et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am. J. Hematol. 96, 934\u2013944. https:\/\/doi.org\/10.1002\/ajh.26209 (2021).","journal-title":"Am. J. Hematol."},{"key":"7489_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102986","author":"A Kronbichler","year":"2021","unstructured":"Kronbichler, A. et al. The COVID-19 pandemic and ANCA-associated vasculitis: Reports from the EUVAS meeting and EUVAS education forum. Autoimmun. Rev. https:\/\/doi.org\/10.1016\/j.autrev.2021.102986 (2021).","journal-title":"Autoimmun. Rev."},{"key":"7489_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab700","author":"J Calder\u00f3n-Parra","year":"2021","unstructured":"Calder\u00f3n-Parra, J. et al. Incidence, clinical presentation, relapses and outcome of SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciab700 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"7489_CR58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/324073a0","volume":"324","author":"T Hirano","year":"1986","unstructured":"Hirano, T. et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324, 73\u201376. https:\/\/doi.org\/10.1038\/324073a0 (1986).","journal-title":"Nature"},{"key":"7489_CR59","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.cell.2020.10.051","volume":"183","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. Cell 183, 1496\u20131507. https:\/\/doi.org\/10.1016\/j.cell.2020.10.051 (2020).","journal-title":"Cell"},{"key":"7489_CR60","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","volume":"182","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell 182, 828\u2013842. https:\/\/doi.org\/10.1016\/j.cell.2020.06.025 (2020).","journal-title":"Cell"},{"key":"7489_CR61","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650. https:\/\/doi.org\/10.1126\/science.abc5902 (2020).","journal-title":"Science"},{"key":"7489_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100126","volume":"1","author":"J Prevost","year":"2020","unstructured":"Prevost, J. et al. Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike. Cell. Rep. Med. 1, 100126. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100126 (2020).","journal-title":"Cell. Rep. Med."},{"key":"7489_CR63","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.chom.2020.09.002","volume":"28","author":"SCA Nielsen","year":"2020","unstructured":"Nielsen, S. C. A. et al. Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2. Cell Host Microbe 28, 516\u2013525. https:\/\/doi.org\/10.1016\/j.chom.2020.09.002 (2020).","journal-title":"Cell Host Microbe"},{"key":"7489_CR64","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.immuni.2020.07.020","volume":"53","author":"C Atyeo","year":"2020","unstructured":"Atyeo, C. et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity 53, 524\u2013532. https:\/\/doi.org\/10.1016\/j.immuni.2020.07.020 (2020).","journal-title":"Immunity"},{"key":"7489_CR65","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/s41467-021-21336-8","volume":"12","author":"YC Bartsch","year":"2020","unstructured":"Bartsch, Y. C. et al. Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nat. Commun. 12, 1018. https:\/\/doi.org\/10.1038\/s41467-021-21336-8 (2020).","journal-title":"Nat. Commun."},{"key":"7489_CR66","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.cell.2020.08.046","volume":"182","author":"C Kreer","year":"2020","unstructured":"Kreer, C. et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell 182, 1663\u20131673. https:\/\/doi.org\/10.1016\/j.cell.2020.08.046 (2020).","journal-title":"Cell"},{"key":"7489_CR67","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442. https:\/\/doi.org\/10.1038\/s41586-020-2456-9 (2020).","journal-title":"Nature"},{"key":"7489_CR68","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2352-4642(20)30177-2","volume":"4","author":"F Gotzinger","year":"2020","unstructured":"Gotzinger, F. et al. COVID-19 in children and adolescents in Europe: A multinational, multicentre cohort study. Lancet Child. Adolesc. Health 4, 653\u2013661. https:\/\/doi.org\/10.1016\/S2352-4642(20)30177-2 (2020).","journal-title":"Lancet Child. Adolesc. Health"},{"key":"7489_CR69","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/ndt\/gfq483","volume":"26","author":"T Sonnweber","year":"2011","unstructured":"Sonnweber, T. et al. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol. Dial Transplant. 26, 977\u2013987. https:\/\/doi.org\/10.1093\/ndt\/gfq483 (2011).","journal-title":"Nephrol. Dial Transplant."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07489-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07489-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07489-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:48:15Z","timestamp":1669333695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07489-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7489"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-07489-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"assertion":[{"value":"13 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3677"}}